Skip to main content
. Author manuscript; available in PMC: 2009 Aug 19.
Published in final edited form as: Toxicology. 2008 Jun 5;250(1):47–54. doi: 10.1016/j.tox.2008.05.018

Figure 4.

Figure 4

Quantitative real-time RT-PCR expression of COX-2 mRNA after treatment with arsenicals and ROS scavengers in UROtsa cells. COX-2 mRNA is increased after arsenical treatment and that increase can be blocked by the addition of ROS scavengers. A) COX-2 expression relative to GAPDH and normalized to UROtsa after 1 μM As(III) for 4 or 24 h, or after 4 h co-treatment with ROS scavengers. B) COX-2 expression relative to GAPDH and normalized to UROtsa after 50 nM MMA(III) for 4 or 24 h, or after 4 h co-treatment with ROS scavengers. Asterisks (*) denote statistically significant changes between As(III) or MMA(III) treated UROtsa levels and those treated with ROS scavengers (p<0.05). (†) Marks statistically significant increase in transcript level when compared with control UROtsa (p≤0.05). (N=3) for all treatment groups.